About the Tazemetostat Clinical Trial ProgramTazemetostat, a first-in-class EZH2 inhibitor, is currently being studied in ongoing Phase 2 programs in patients with NHL. It is also being studied in adult and pediatric patients with certain genetically defined solid tumors, including INI1-negative and SMARCA4-negative tumors and synovial sarcoma, and in patients with mesothelioma.The company plans to initiate additional clinical trials of tazemetostat in 2016, including a combination with R-CHOP in collaboration with the Lymphoma Study Association and a combination with Tecentriq™ (atezolizumab) in collaboration with Genentech, a member of the Roche Group. About SmartTrials Precision Enrollment Program and FoundationOne ® HemeFoundation Medicine's SmartTrials Precision Enrollment program leverages the company's unique combination of broad collaborations with biopharma, industry-leading clinical assays and the FoundationCORE™ genomic knowledgebase with more than 90,000 real-world genomic profiles to overcome the major roadblocks to today's clinical trial system, namely patient identification and access to trials. FoundationOne ® Heme, an integrated DNA/RNA platform using targeted hybrid-capture next-generation sequencing, is a comprehensive genomic profile developed to detect genomic alterations with therapeutic relevance, including single-nucleotide substitutions, insertions and deletions, copy number alterations and rearrangements, which are not fully evaluated using conventional diagnostic assays. FoundationOne ® Heme simultaneously detects all classes of genomic alterations in the DNA of 405 cancer-related genes and employs RNA sequencing across 265 genes to capture a broad range of gene fusions, a type of alteration that is a common driver of hematologic cancers. It is designed to provide physicians with clinically actionable information to guide treatment options for patients based on the genomic profile of their cancer. About Epizyme, Inc. Epizyme, Inc. is a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics for people with cancer. Epizyme has built a proprietary product platform to create small molecule inhibitors of chromatin modifying proteins (CMPs), such as histone methyltransferases (HMTs). CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients. For more information, visit www.epizyme.com. Cautionary Note on Forward-Looking StatementsAny statements in this press release about future expectations, plans and prospects for Epizyme, Inc. and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plans," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation of future clinical studies, availability and timing of data from ongoing clinical studies, whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials, expectations for regulatory approvals, whether the Company's collaborations will be successful, including the collaboration with Foundation Medicine, availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements, other matters that could affect the availability or commercial potential of the Company's therapeutic candidates or companion diagnostics and other factors discussed in the "Risk Factors" section of our Form 10-Q most recently filed with the SEC, and in our other filings from time to time with the SEC. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. Foundation Medicine ® and FoundationOne Heme ® are registered trademarks, and SmartTrials™ is a trademark, of Foundation Medicine, Inc. Tecentriq™ is a trademark of Genentech, Inc., (South San Francisco, CA, USA), a member of the Roche Group.
Epizyme Investors and Media Contact:Julie DiCarlo, Epizyme, Inc. email@example.com(617) 401-0721